Skip to main content
Testing version — LOERadar is in active testing. Features and data may change.
LOERadar
LOE
Radar
Hub
News
Changes
Search
Log in
Get Started
UKONIQ (UMBRALISIB TOSYLATE) | LOERadar
Viewing data from:
Latest
2026-07-01
2026-06-01
2026-05-01
2026-04-01
2026-03-28
2026-02-17
2026-02-10
2025-12-14
2025-02-26
2025-01-25
2024-11-08
2023-07-23
2023-06-15
2023-05-13
2023-01-26
2022-11-22
2022-10-28
2022-09-29
2022-07-09
2022-06-29
2022-04-08
2022-03-09
2021-12-28
2021-05-05
2021-03-12
2020-12-22
2020-11-12
2019-12-14
2019-09-15
UKONIQ
NDA
Get alerts
UMBRALISIB TOSYLATE | N213176 | TG THERAPEUTICS INC
1 strength
8 unique patents
1 unique exclusivity
Patents
SEC Intel
Revenue
PTAB
Reexams
Litigation
Petitions
Trials
Approvals
Label
Products
Patent Timeline
8 unique patents, 1 exclusivity by expiration date
Active (8)
Today
Exclusivity
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
Today
9150579
Jul. 2, 2033
9669033
Jul. 2, 2033
9969740
May. 26, 2035
10072013
Jul. 2, 2033
10414773
May. 26, 2035
10570142
Jul. 2, 2033
10947244
May. 26, 2035
10981919
Jul. 2, 2033
NCE
Feb. 5, 2026
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — EQ 200MG BASE
RLD
8 patents
1 exclusivity
▴
TABLET;ORAL | Approved: Feb 5, 2021
Patents (8)
Patent #
Expiration
PED
Drug Substance
Drug Product
Use Code
Delist
9150579
Jul 2, 2033
—
Yes
Yes
—
—
9669033
Jul 2, 2033
—
—
—
U-3063
RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
—
9969740
May 26, 2035
—
Yes
Yes
U-3064
RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
—
10072013
Jul 2, 2033
—
—
—
U-3063
RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
—
10414773
May 26, 2035
—
Yes
Yes
U-3063
RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
—
10570142
Jul 2, 2033
—
Yes
Yes
U-3064
RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY
—
10947244
May 26, 2035
—
—
—
U-3063
RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
—
10981919
Jul 2, 2033
—
—
—
U-3063
RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN
—
Exclusivities (1)
Code
Date
Status
NCE
Feb 5, 2026
Expired